Azetidinones as vasopressin V1a antagonists was written by Guillon, Christophe D.;Koppel, Gary A.;Brownstein, Michael J.;Chaney, Michael O.;Ferris, Craig F.;Lu, Shi-Fang;Fabio, Karine M.;Miller, Marvin J.;Heindel, Ned D.;Hunden, David C.;Cooper, Robin D. G.;Kaldor, Stephen W.;Skelton, Jeffrey J.;Dressman, Bruce A.;Clay, Michael P.;Steinberg, Mitchell I.;Bruns, Robert F.;Simon, Neal G.. And the article was included in Bioorganic & Medicinal Chemistry in 2007.Safety of 1-Propylpiperazine This article mentions the following:
The azetidinone LY307174 (I) was identified as a screening lead for the vasopressin V1a receptor (IC50 45 nM at the human V1a receptor) based on mol. similarity to ketoconazole, a known antagonist of the LH releasing hormone receptor. Structure-activity relationships for the series, e.g., II, were explored to optimize receptor affinity and pharmacokinetic properties, resulting in compounds with K i values <1 nM and brain levels after oral dosing ∼100-fold higher than receptor affinities. Display Omitted. In the experiment, the researchers used many compounds, for example, 1-Propylpiperazine (cas: 21867-64-1Safety of 1-Propylpiperazine).
1-Propylpiperazine (cas: 21867-64-1) belongs to piperazine derivatives. Industrial applications of piperazine include the manufacture of plastics, resins, pesticides and brake fluids. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful. Safety of 1-Propylpiperazine
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics